GRAIL, Inc. (GRAL)
| Market Cap | 3.11B |
| Revenue (ttm) | 134.29M |
| Net Income (ttm) | -442.95M |
| Shares Out | 36.05M |
| EPS (ttm) | -13.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 424,817 |
| Open | 84.33 |
| Previous Close | 85.00 |
| Day's Range | 82.46 - 86.76 |
| 52-Week Range | 12.76 - 103.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 52.50 (-39.21%) |
| Earnings Date | Nov 12, 2025 |
About GRAL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it... [Read more]
Financial Performance
In 2024, GRAIL's revenue was $125.60 million, an increase of 34.90% compared to the previous year's $93.11 million. Losses were -$2.03 billion, 38.3% more than in 2023.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for GRAL stock is "Buy." The 12-month stock price target is $52.5, which is a decrease of -39.21% from the latest price.
News
GRAIL: Buy Τhe Test That Could Redefine Cancer Screening
GRAIL moves from scientific vision to proven clinical reality, as PATHFINDER 2 confirms that multi-cancer early detection works effectively at scale. Physician and patient adoption is accelerating, su...
Odds of these speculative stocks making you money seems very slim, says Jim Cramer
CNBC's Jim Cramer discusses the day's market action and his take on speculative stocks.
GRAIL, Inc. (GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection Transcript
GRAIL, Inc. (NASDAQ:GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection October 20, 2025 8:00 AM EDT Company Participants Robert Ragusa - CEO & Director Jo...
GRAIL, Inc. Announces $325.0 Million Private Placement Financing
MENLO PARK, Calif. , Oct. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has entered in...
GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)
One-Third of Participants Initially Believed to Have a False-Positive Result Were Later Diagnosed With Cancer During Follow Up Updated Positive Predictive Value of Galleri in This Symptomatic Populati...
GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings PATHFINDER 2 is the Largest U.S. Multi-Cancer...
What's Happening With GRAIL Stock?
GRAIL shares soared 14% on October 16, 2025, after the announcement of a strategic partnership with Samsung C&T and Samsung Electronics to introduce the company's Galleri multi-cancer early detection ...
Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia
Samsung C&T and Samsung Electronics Will Make an Equity Investment of $110 Million Into GRAIL, Subject to Closing Conditions Samsung C&T Will Drive Commercialization of Galleri in South Korea With Pos...
Grail: A Speculative Buy
Grail, Inc. represents a speculative long-term investment opportunity, conditional on the FDA's approval of its Galleri multi-cancer early detection blood test and its widespread adoption among the ge...
GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC
First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket A...
Sun World International and Pairwise Launch Strategic Partnership to Develop a Holy Grail of Produce – the Pitless Cherry
Joint Venture Combines Advanced Plant Breeding Technology with Global Fruit Expertise to Deliver Consumer-Desired Traits Joint Venture Combines Advanced Plant Breeding Technology with Global Fruit Exp...
GRAIL to Present at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
MENLO PARK, Calif. , Sept. 10, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company manageme...
GRAIL, Inc. (GRAL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
GRAIL, Inc. (NASDAQ:GRAL) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Robert Ragusa - CEO & Director Aaron Freidin - Chief Financial Off...
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Aug. 29, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted eq...
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
GRAIL to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
MENLO PARK, Calif. , Aug. 26, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
GRAIL, Inc. (GRAL) Q2 2025 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Aaron Freidin - Chief Financial Officer Andrew John Partridge - Chief Commercial Officer Har...
GRAIL Reports Second Quarter 2025 Financial Results
Q2 U.S. Galleri Revenue Grew 21% Year-Over-Year to $34.2 Million Q2 Galleri Tests Sold Grew 29% Year-Over-Year to More Than 45,000 Detailed Results From First 25,000 Enrolled in PATHFINDER 2 to be Sub...
GRAIL to Present at Canaccord Genuity 45th Annual Growth Conference
MENLO PARK, Calif. , July 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
GRAIL to Announce Second Quarter 2025 Financial Results
MENLO PARK, Calif. , July 29, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue fin...
The Holy Grail of Automation: Now a Robot Can Unload a Truck
Technology breakthroughs are allowing DHL and other companies to automate the laborious, injury-prone work of loading and unloading.
Grail Shares Jump on Promising Results for Galleri Study
Shares of Grail climbed after the company said the second study of its Galleri multi-cancer early detection test provided even more promising results than the first.
GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study
Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study MENLO PARK, Calif. , June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a heal...
GRAIL to Present at Jefferies Global Healthcare Conference 2025
MENLO PARK, Calif. , May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management...
Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.